SEngine Precision Medicine

We turned a lot of heads and generated serious attention when SEngine Precision Medicine's Rachele Rosati presented a paper with this title: "Ex Vivo Drug Testing Identifies a Potentially Effective Drug in 94% of Cases for 418 Samples and 383 Patients in 46 Different Tumor Types." The foundation for how we do this is a functional approach: the PARIS® Test. I explain this process below. And what makes this remarkable it that it's patient-driven. For years patients asked us to develop a test like this, and now it's achieving remarkable results. #paristest #functionalprecisionmedicine #oncology #cancerresearch #patientdriven #functionalapproach

"Ex Vivo Drug Testing Identifies a Potentially Effective Drug in 94% of Cases for 418 Samples and 383 Patients in 46 Different Tumor Types." That's the title of Rachele Rosati's presentation given last week at the American Association for Cancer Research (AACR). She's our Director of the Cancer Organoid Core. Our work continues to gain the attention of the cancer research community! #cancerresearch #organoid #aacr #functionalprecisionmedicine #paristest

Why not? That's the question my co-founder Christopher Kemp posed when it comes to looking at new cancer treatment alternatives that can be found using SEngine Precision Medicine's PARIS® Test. Why not is also what patients asked us when we considered developing the PARIS Test. And so we developed it -- with the result that we've given many patients with few remaining standard-of-care treatments left available to them new options for fighting their disease. Nature has also covered our progress: https://lnkd.in/dfbxwXJ4 #whynot #paristest #functionalprecisionmedicine #cancerresearch

So how does the PARIS® Test work? This is what we've been using at SEngine Precision Medicine to find new therapies for cancer patients. The succes we've had with the PARIS Test has also led to this article in Nature: https://lnkd.in/dfbxwXJ4 I explain this process below. And 'ex vivo' means it works outside the body, too. #cancerresearch #functionalmedicine #functionalprecisionmedicine #paristest

It was a very emotional day to reunite with one of our patients who had the PARIS® Test way back in 2022. Two years later she is doing well, so well that it made me cry. I knew it was not all rosy for her but the targeted drugs based on the functional PARIS Test have kept her disease under control. She has been driving her care, providing data to her physician -- who has listened. I believe her story should be shared with other cancer patients, in particular ovarian cancer patients. Hers is a low grade ovarian cancer that occurs in young women and mothers with young children, like this patient.   Could this disease, LGSOC, be turned like Chronic Myelogenous Leukemia (CML) into a non-life threatening chronic condition? With a good quality of life? Just taking a pill or drug combinations of targeted therapies at low concentrations to enable long term treatment? The PARIS Test showed her the way and I am so grateful for the patients that pushed us to develop this. #functionalprecisionmedicine #functionaloncology #LGSOC #CML #paristest SEngine Precision Medicine #precisionmedicine #livingstrong #ovariancancer

The PARIS® Test we've developed is patient-driven. Through the years, patients asked for us to come up with a way of finding new treatment options for difficult-to-treat cancers. But some oncologists have been reluctant to embrace this new direction. Yet the success we've had with this functional precision medicine approach led to a recent article in Nature (https://lnkd.in/dfbxwXJ4) that featured SEngine Precision Medicine's work. SEngine Co-Founder, Christopher Kemp advises that patients can now point to this article -- and the fact that it's being discussed in global circles -- to ask a reluctant oncologist to order a PARIS Test. This is especially true when a patient may be exhausting standard-of-care treatment options. But it's also relevant for patients earlier in their cancer treatments to evaluate all avenues that are open to them for fighting their cancer. As one of our patients says, the PARIS Test is opening up the medicine cabinet to give patients more options. #oncologyresearch #functionalprecisionmedicine #organoids #paristest #cancerresearch #medicinecabinet #naturejournal

As a recent article in Nature noted, the future of functional precision medicine might be to try to throw everything at treating a particular cancer. This is why SEngine Precision Medicine was featured in Nature -- because we're doing something similar and it's showing results. Many of our patients have exhausted their options for standard of care therapies, so why not open the medicine cabinet (as one of our patients says)? Why not try other treatments to see if they make a difference? As I mention below, this is also common in genomic precision medicine. Our solution, called the PARIS® Test, was created because patients requested it -- and it's finding new treatment options for many fighting cancer. Here's the link to the Nature article: https://lnkd.in/dfbxwXJ4 #functionalmedicine #functionalprecisionmedicine #cancerresearch #organoids #standardofcare #oncologyresearch

SEngine Precision Medicine received some stellar coverage in the journal Nature about how we're finding new cancer therapy options for patients. SEngine co-founder Christopher Kemp breaks down what that means -- and how our approach is quite effective. As Chris says, if you're fighting cancer, there's little reason you wouldn't want to consider the PARIS® Test as a resource in your fight. We're also getting the word out about our functional precision medicine advances worldwide. Here's the Nature article: https://lnkd.in/dfbxwXJ4 #functionalprecisionmedicine #functionalmedicine #functionaloncology #paristest #organoids

Fred Hutch's Christopher Kemp, PhD, recently received a five-year, $5.4 million grant from the National Cancer Institute (NCI) to use leading-edge functional genomics approaches to uncover new cancer therapy targets in tumor tissues donated by patients. The team has developed a method to grow patient-derived tumor cells in tumor-like 3D structures called organoids, which better capture tumor behavior and enable them to uncover promising new vulnerabilities. “We have an unbiased approach to search for new treatment targets beyond what we already have,” Kemp said. “It’s ground truth, directly from a patient. What could be more relevant than that?” Read more: https://bit.ly/4c9MXFx

It's great to get feedback on the article in Nature where SEngine Precision Medicine is featured. (I'll provide a link to the article below.) What's gratifying is to get recognized in such an important publication so many scientists rely on because our hunch -- based on research -- worked. We have literally come full circle. Our PARIS® Test approach offers new treatment options for the majority of cancer patients who take the test. Here's the Nature article: https://lnkd.in/dfbxwXJ4 #functionalprecisionmedicine #cancerresearch #canceroncology #organoid